Pfizer bets its comeback on an obesity pipeline as COVID windfall fades and patent cliffs loom

Pfizer is entering a tougher stretch as the financial surge from its COVID-19 vaccine and treatments recedes and major patent protections start to expire. In a post-pandemic environment marked by pipeline setbacks and intensifying competition, the company is shifting more attention to a reshaped obesity pipeline, hoping it can become a meaningful engine of growth.

The anxiety is not just about near-term demand. Pfizer faces what industry observers describe as a widening “patent cliff,” with exclusivity losses expected to create a $1.5 billion headwind, with that pressure projected to swell to $4.5 billion in 2027, Pfizer CEO Dr. Albert Bourla said in January, according to a recent industry account. The same reporting points to a broader wave of earlier blockbuster expirations, where five Pfizer products together generated about $21.9 billion in sales last year, roughly one-third of the company’s total revenue.

The company is also trying to reposition its research and commercialization strategy. In the PharmaVoice report, strategic consultant Jacqui Poot said Pfizer has “dropped out of the top 10 in innovation” in an index ranking companies by R&D and commercialization achievements. She also described Pfizer as “stalling at the moment,” saying the company is having difficulty navigating the post-COVID era.

To close gaps created by those setbacks and looming losses, Pfizer has been investing heavily in external growth as well as internal development. Bourla said Pfizer has been revamping its pipeline strategy and has been pouring more than $80 billion into acquisitions and licensing deals to bolster its portfolio and help offset expected revenue declines.

Even with that spend, the company’s obesity focus is central to the narrative of a comeback. Pfizer’s newly restructured and diversified obesity pipeline is projected to bring in around $20 billion in revenue by 2030, according to the PharmaVoice account. The report frames the obesity push as a possible pathway for Pfizer to climb back toward top-tier R&D performance, rather than relying on the kind of blockbuster releases that powered its earlier eras.

Bourla’s public messaging suggests obesity is part of a wider shift toward areas he considers “revolutionary” in drug development, including GLP-1-type approaches that have reshaped the weight-loss market. While those comments are not a financial forecast on their own, they reinforce that Pfizer sees obesity and related metabolic therapies as an important strategic theme going forward.

Still, there are clear limits to what can be concluded from the available reporting. The PharmaVoice post does not provide specific trial outcomes, regulatory timelines, or detailed revenue assumptions tied to particular obesity candidates. It also does not indicate how much of the $20 billion by 2030 is contingent on approvals, label expansions, or competitive dynamics. Likewise, while other coverage has pointed to near-term margin and profit pressure tied to fading COVID revenues, it does not, in the cited material here, connect those pressures directly to obesity-specific milestones.

What to watch next is whether Pfizer’s obesity efforts can translate pipeline promise into clinical and commercial progress, including whether any candidates secure the approvals and market positioning needed to justify the projected contribution. Investors and analysts are likely to look for updates that clarify timelines, competitive differentiation, and the degree to which acquisitions and licensing deals lower the probability of future misses as patent cliffs approach.